Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA901 plus sunitinib versus sunitinib alone in first-line advanced renal cell carcinoma
NL-OMON36272Phase 3Active, not recruiting
- Sponsor
- Immatics
- Start
- Apr 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of IMA901, sunitinib, sargramostim and cyclophosphamide in renal cell carcinoma (RCC) (2 arms), sponsored by Immatics. Primary endpoint: Overall survival. Started Apr 2012; status: active, not recruiting.
02
Drugs
IMA901sunitinibsargramostimcyclophosphamide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON36272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36272.